Spots Global Cancer Trial Database for A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Official Title: A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies
Study ID: NCT03995472
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia
Scientia Clinical Research, Randwick, New South Wales, Australia
Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia
John Flynn Private Hospital, Tugun, Queensland, Australia
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Contact Details
Name: Yilong Wu, MD
Affiliation: Guangdong General Hospital & Guangdong Academy of Medical Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
